<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200610047725N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-18</date_registration>
      <primary_sponsor>Yasouj University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of aromatherapy and edible rose essential oil on saliva cortisol level and quality of life of chronic renal failure patients undergoing hemodialysis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of aromatherapy and edible rose essential oil on saliva cortisol level and quality of life of chronic renal failure patients undergoing hemodialysis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51312</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Eligible participants will be selected by purposive sampling from the available population and will be allocated through random block allocation to intervention group No.1 (aromatherapy) and intervention group No.2 (oral intake). In this way, by multiplying the number of studied groups (two groups) by 2, the number of samples of each block was calculated as 4. Then, through factorial calculation, the number of blocks resulting from all arrangement modes of people was calculated as 24 blocks (4! = 4 x3 x2 x1 = 24). Possible arrangement blocks of people will be A (gray dummy) for the intervention group No.1 (aromatherapy) and B (white dummy) for intervention group No.2 (oral intake). Since the number of people in each block is 4 people and the estimated sample size is 72 people, therefore by matching 18 random numbers generated by the Sample Randomizer software, The arrangement of people in the research sample and the allocation of each number from 1 to 72 to each one of the intervention group No. 1 (aromatherapy) and intervention group No. 2 (oral consumption) will be determined. Then the block random allocation list will be compiled. In the following, patients suffering from chronic renal failure under hemodialysis will be referred and qualified research samples will be selected by fully explaining the objectives of the study. Based on the priority of the referral, a code is assigned to each of them, and by matching that number with the random block allocation list, the patients participating in the research will be assigned to one of the groups of intervention number 1 (aromatherapy) and intervention number 2 (oral intake) ) will be allocated. This process will continue until the estimated sample size is completed.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Patients with chronic renal failure under hemodialysis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group number 1 (aroma therapy): When the patient is connected to the dialysis machine, a piece of cloth soaked in 3 drops of rose essence with a concentration of 2% is attached to the patient's neck and the patient will be asked to breathe normally. This work will be done 3 times a day and each time for 5 minutes for 4 weeks. Intervention 2: Intervention group number 2 (oral intake): When the patient is connected to the dialysis machine, 15 drops of rose extract will be poured into some water every 8 hours and given to him/her. Totally, 3 doses of medicine will be given to the patient daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tahereh Taheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 6, 7th Saadi Alley, Old Terminal, Yasuj, Iran.</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591974433</zip>
        <telephone>+98 74 3322 1350</telephone>
        <email>t60.taheri@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Taheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 6, 7th Saadi Alley, Old Terminal, Yasuj, Iran.</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591974433</zip>
        <telephone>+98 74 3322 1350</telephone>
        <email>t60.taheri@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Ability to communicate and answer questions
Consent to participate in the study and sign the informed consent form
Healthy sense of smell
Not having an anxiety disorders
Not having a history of using aromatherapy
Not having asthma and allergies
Not brushing teeth
At least three months have passed since hemodialysis
Doing dialysis at least 2 to 3 times a week
Not taking corticosteroids and immunosuppressants
Not having active infection
Not having a history of organ transplant rejection
Dialysis in the morning shift
No history of cancer</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to Rosa damascene and patient reaction to it
Taking anti-anxiety and anti-depressant drugs
Performing a kidney transplant during the study
Change of dialysis method from hemodialysis to peritoneal dialysis during the intervention
Hospitalization in the intensive care unit during the intervention</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease, stage 5</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group number 1 (aroma therapy): When the patient is connected to the dialysis machine, a piece of cloth soaked in 3 drops of rose essence with a concentration of 2% is attached to the patient's neck and the patient will be asked to breathe normally. This work will be done 3 times a day and each time for 5 minutes for 4 weeks.</i_keyword>
      <i_keyword>Intervention group number 2 (oral intake): When the patient is connected to the dialysis machine, 15 drops of rose extract will be poured into some water every 8 hours and given to him/her. Totally, 3 doses of medicine will be given to the patient daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Salivary cortisol levels. Timepoint: Salivary cortisol levels at the beginning of the study (before the intervention) and one month later. Method of measurement: By ELISA kits.</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: Quality of life at the beginning of the study (before the intervention) and one month later. Method of measurement: Kidney Disease Quality of Life-Short Form (KDQOL-SF) questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yasouj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-03</approval_date>
        <contact_name>Ethics committee of Yasuj University of Medical Sciences</contact_name>
        <contact_address>Yasuj University of Medical Sciences, Shahid Motahari Blvd., Yasuj, Iran. Yasuj Kohgilouyeh-va-Boyrahmad Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
